TransCode Therapeutics, Inc. (RNAZ) Q4 2024 Earnings
RNAZ·Reported March 28, 2025
Diluted EPS came in at $-16.61, beat the $-105.93 consensus by $89.32.
Diluted EPS
$-16.61beat by $89.32
Consensus: $-105.93
SEC Filings
Earnings release8-K not filed yet
Quarterly report10-Q / 10-K not filed yet
Filings will appear here once submitted to SEC EDGAR.
Q4 2024 Earnings FAQ
Common questions about TransCode Therapeutics, Inc.'s Q4 2024 earnings report.
TransCode Therapeutics, Inc. (RNAZ) reported Q4 2024 earnings on March 28, 2025.
TransCode Therapeutics, Inc. reported diluted EPS of $-16.61 for Q4 2024.
EPS beat the consensus estimate of $-105.93 by $89.32.